Hepatocellular Carcinoma Pipeline Appears Robust With 90+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Hepatocellular Carcinoma Pipeline Insight 2025' report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Hepatocellular Carcinoma Treatment Landscape. Click here to read more @ Hepatocellular Carcinoma Pipeline Outlook
Key Takeaways from the Hepatocellular Carcinoma Pipeline Report
In May 2025, Coherus Biosciences Inc. announced a phase 2 trial composed of an open label Lead-In followed by a Randomized Phase designed to evaluate the efficacy and safety of SRF388 in combination with atezolizumab plus bevacizumab compared to placebo (inactive substance) in combination with atezolizumab plus bevacizumab in patients with first-line advanced or metastatic HCC.
DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.
The leading Hepatocellular Carcinoma Companies such as Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
Promising Hepatocellular Carcinoma Therapies such as Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
Discover groundbreaking developments in Hepatocellular Carcinoma therapies! Gain in-depth knowledge of key Hepatocellular Carcinoma clinical trials, emerging drugs, and market opportunities @ Hepatocellular Carcinoma Clinical Trials Assessment
Hepatocellular Carcinoma Emerging Drugs
• Namodenoson: Can-Fite BioPharma
Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5'- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). The drug had been out-licensed to Chong Kun Dang (CKD) Pharmaceutical in Korea and to CMS in China.for the treatment of Hepatocellular Carcinoma and NASH. A Phase I/II study in hepatocellular carcinoma (HCC) successfully met its primary and secondary endpoints demonstrating initial indications for efficacy of Namodenoson. A global Phase II study treating patients with Namodenoson as a second-line therapy has recently been concluded.
• SRF388: Surface Oncology
SRF388 is a fully human anti-IL-27 antibody designed to inhibit the activity of this immunosuppressive cytokine. IL-27 is an immunosuppressive cytokine involved in resolving T cell mediated inflammation. Recent data points to IL-27 as a master regulator of the expression of co-inhibitory receptors expressed on CD4+ and CD8+ T cells. Elevated levels of IL-27 transcripts and mRNA gene signatures are found in cancer and are associated with poor prognoses. Surface Oncology has identified particular tumor types where IL-27 appears to play an important role in the immunosuppressive tumor microenvironment and may contribute to resistance to treatment with checkpoint inhibitors.
• Porustobart: Harbour BioMed
Porustobart (HBM4003) is a fully human anti-CTLA-4 monoclonal heavy chain only antibody (HCAb) generated from mice. By enhancing antibody-dependent cell cytotoxicity (ADCC) killing activity, porustobart has demonstrated significantly improved depletion specific to high CTLA-4 Treg cells in tumor tissues. The potent anti-tumor efficacy and differentiated pharmacokinetics with durable pharmacodynamic effect presents a favorable product profile. This novel and differentiated mechanism of action has the potential to improve efficacy while significantly reducing the toxicity of the drug in monotherapy and combo-therapy.
• Fisogatinib: CStone Pharmaceuticals
Fisogatinib is an orally available, potent, irreversible inhibitor of FGFR4. Fisogatinib was specifically designed to inhibit FGFR4 with exquisite selectivity, thereby sparing the paralogs FGFR1, FGFR2 and FGFR3 and preventing potential adverse effects. Preclinical data has validated FGFR4 as an oncogenic driver for a subset of patients with advanced HCC. The US Food and Drug Administration has granted orphan drug designation to fisogatinib for the treatment of HCC. Fisogatinib is being investigated in the Phase I/II stage of its development for the treatment of patients with FGFR4-activated HCC.
• STP705: Sirnaomics
STP705 is composed of two siRNA oligonucleotides targeting TGF-β1 and COX-2 mRNA respectively and formulated in nanoparticles with a proprietary Histidine-Lysine Co-Polymer (HKP) peptide. Each individual siRNA has demonstrated the ability to inhibit the expression of their target mRNA and combining the two siRNAs produces a synergistic effect that diminishes pro-fibrogenic, pro-inflammatory, and pro-tumorigenic factors. Sirnaomics has completed several pre-clinical studies that demonstrate that inhibition of TGF-β1 and COX-2 and is expected to result in the inhibition of tumor growth and provide an alternative approach for the treatment of various Hepatocellular Carcinomas. Molecular analyses of the effects of administering the combination demonstrated that the inhibition of these targets had effects on downstream gene products associated with numerous oncology targets.
The Hepatocellular Carcinoma Pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Hepatocellular Carcinoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatocellular Carcinoma Treatment.
Hepatocellular Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Hepatocellular Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatocellular Carcinoma market.
Stay informed about the Hepatocellular Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Hepatocellular Carcinoma Unmet Needs
Hepatocellular Carcinoma Companies
Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others.
Hepatocellular Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
Hepatocellular Carcinoma Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
Transform your understanding of the Hepatocellular Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Hepatocellular Carcinoma Market Drivers and Barriers, and Future Perspectives
Scope of the Hepatocellular Carcinoma Pipeline Report
Coverage- Global
Hepatocellular Carcinoma Companies- Can-Fite BioPharma, Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Shenogen Pharma, GlaxoSmithKline, Tarus Therapeutics, Tvardi Therapeutics, Virogin Biotech, Yiviva, Chia Tai Tianqing Pharmaceutical Group, Antengene Corporation, Iterion Therapeutics, Sumitomo Pharma, SillaJen Biotherapeutics, SCG Cell Therapy, Guangdong ProCapZoom Biosciences, Eutilex, Polaris Pharmaceuticals, OriCell Therapeutics, and others
Hepatocellular Carcinoma Therapies- Pembrolizumab, Tislelizumab, HLX53 (1000mg), Atezolizumab, Bevacizumab, Tiragolumab, Nivolumab and others
Hepatocellular Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hepatocellular Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Stay Ahead in Oncology Research–Access the Full Hepatocellular Carcinoma Pipeline Analysis Today! @ Hepatocellular Carcinoma Drugs and Companies
Table of Content
1. Introduction
2. Executive Summary
3. Hepatocellular Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Hepatocellular Carcinoma- DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Namodenoson: Can-Fite BioPharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. SRF388: Surface Oncology
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. STP705: Sirnaomics
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Hepatocellular Carcinoma Key Companies
21. Hepatocellular Carcinoma Key Products
22. Hepatocellular Carcinoma- Unmet Needs
23. Hepatocellular Carcinoma- Market Drivers and Barriers
24. Hepatocellular Carcinoma- Future Perspectives and Conclusion
25. Hepatocellular Carcinoma Analyst Views
26. Hepatocellular Carcinoma Key Companies
27. Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
42 minutes ago
- Globe and Mail
AMD, INTC, or NVDA: Which Chip Stock Is Wall Street's Best Pick?
Easing chip restrictions and trade negotiations have improved the sentiment for chip stocks, though worries about macro uncertainty and increased competition continue to be an overhang. Nonetheless, Wall Street remains bullish on some chip stocks, mainly due to robust demand for advanced chips to support the ongoing AI (artificial intelligence) boom. Using TipRanks' Stock Comparison Tool, we placed Advanced Micro Devices (AMD), Intel (INTC), and Nvidia (NVDA) against each other to find the best chip stock, according to Wall Street analysts. Confident Investing Starts Here: Advanced Micro Devices (NASDAQ:AMD) Advanced Micro Devices stock has advanced 4% in the past month due to favorable news on chip export restrictions and tariffs. However, AMD stock is still down 3.5% year-to-date, as worries about macro woes and the company lagging the AI race continue to weigh on market sentiment. Last month, AMD impressed investors with its upbeat first-quarter results, strong performance of the data center segment, and solid guidance. However, investors continue to await more aggressive growth in the AI space. At the Advancing AI event held on June 12, AMD CEO Lisa Su spoke about the company's MI350 series and MI400 series AI chips, which are expected to compete with Nvidia's Blackwell processors. Further, the MI400 series of chips will be the basis for AMD's new server called Helios, which the company plans to release next year to compete with Nvidia's NVL72 servers. However, the much-anticipated Advancing AI event failed to move AMD stock higher, as the chips discussed at the event might not immediately change the company's competitive position. Is AMD Stock a Buy or Sell Now? Following the Advancing AI event, Baird analyst Tristan Gerra reiterated a Buy rating on AMD stock with a price target of $140. The 4-star analyst noted that AMD raised its AI accelerator total addressable market (TAM) estimate to more than $500 billion by 2028, up from the prior estimate of $500 billion, representing over 60% compound annual growth rate (CAGR). The company expects the inferencing market to grow by above an 80% CAGR during this time. The analyst noted the products showcased by the company, including the MI350 series, MI355x, and the Helios AI rack. He also mentioned the AMD Developer Cloud, which will provide users access to a fully managed cloud environment. Overall, Wall Street has a Moderate Buy consensus rating on Advanced Micro Devices stock based on 22 Buys and 10 Holds. The average AMD stock price target of $127.93 indicates about 8% upside potential. See more AMD analyst ratings Intel (NASDAQ:INTC) Chipmaker Intel has been struggling in recent years due to the continued loss of share in the CPU market to AMD, a lack of innovation, strategic missteps, persistent delays in product launches, and instability in the management team. While Intel CEO Lip-Bu Tan is trying to revive the business by improving efficiency, reducing costs, and launching new products, several analysts remain cautious on Intel due to the uncertainty about its turnaround, given the company's unimpressive performance and poor execution in recent years. Also, investors are increasingly concerned about Intel losing the opportunity to capture the massive demand for advanced chips needed in AI models. Is Intel Stock a Buy or Sell? Recently, Deutsche Bank analyst Ross Seymore initiated coverage of Intel stock with a Hold rating and price target of $23. The 5-star analyst believes that despite the turnaround efforts, investors will still have to show patience, as Intel navigates macro uncertainties and company-specific headwinds related to high manufacturing costs and a lack of leading products. While Seymore has confidence in Tan's leadership and the higher odds of a successful turnaround under his guidance, he pointed out the absence of formal details of his strategic vision. Seymore believes that the road to Intel generating notable EPS/free cash flow remains unclear and highly dependent on a turnaround in the foundry business, which he contends is 'no small feat.' He expects Intel to deliver EPS of about $2 by 2027 if the company successfully restructures its manufacturing processes, product roadmap, and customer wins in the foundry business. Turning to Wall Street, Intel stock has a Hold consensus rating based on one Buy, 26 Holds, and four Sell ratings. The average INTC stock price target of $21.30 implies a modest upside of 2.5%. Intel stock has risen just 1.4% so far in 2025. See more INTC analyst ratings Nvidia (NASDAQ:NVDA) After struggling earlier in the year, Nvidia stock has risen about 10% over the past month, bringing the year-to-date gains to 6.4%. The company addressed investors' concerns with its market-beating results for the first quarter of Fiscal 2026. Moreover, easing chip export restrictions and favorable agreements that eased trade war tensions helped improve investor sentiment. Meanwhile, Nvidia continues to announce major deals that reflect robust demand for the company's GPUs (graphics processing units) that are required for AI workloads. Notably, the company is focusing on international expansion to capture solid AI opportunities. This week, Nvidia announced multiple partnerships with European countries and companies, under which it would offer AI infrastructure and software solutions. One of the notable partnerships is with French startup Mistral. Under this deal, the French company will build an AI cloud that will deploy 18,000 Nvidia Grace Blackwell chips, allowing businesses to develop and use AI via Mistral's models. Is NVDA Stock a Buy Right Now? Following Nvidia's GTC event in Paris, France, UBS analyst Timothy Arcuri reiterated a Buy rating with a price target of $175. The analyst stated that the Paris event reinforced that NVDA's 'demand funnel' is expanding from a handful of U.S. hyperscalers to sovereign states and brownfield industries, creating the possibility of upward revisions to estimates. Arcuri noted that Nvidia now has a line of sight to about $1.5 trillion of AI infrastructure investment over the next several years, consistent with the company's prior commentary on a pipeline of 'tens of gigawatts' of projects within a 2 to 3 year timeframe and $40 to $50 billion of revenue per gigawatt of AI data center capacity. This, according to Arcuri, indicates Nvidia's data center revenue in the range of $400 billion per year or about 2x his $233 billion estimate for calendar year 2026. He believes that such impressive estimates should address investors' concerns around a near – or even medium-term EPS peak. With 35 Buys, four Holds, and one Sell recommendation, Wall Street has a Strong Buy consensus rating on Nvidia stock. At $172.36, the average NVDA stock price target implies about 19% upside potential. Conclusion Wall Street is sidelined on Intel stock, modestly bullish on AMD stock, and highly optimistic on Nvidia stock. Analysts see higher upside potential in Nvidia stock than in the other two chip stocks. Wall Street sees continued strength in Nvidia's business, driven by its innovation, solid execution, and the demand for its advanced offerings in the ongoing AI wave.
Globe and Mail
3 hours ago
- Globe and Mail
Warren Buffett Says to Buy This Vanguard ETF. It Could Turn $1,000 Per Month Into $245,000 in 10 Years.
Top fund managers consistently select individual stocks to build high-performing portfolios. While individual investors often believe they can do the same, and some actually might, the vast majority of people aren't as skilled at stock selection. Here's where the recommendation of Warren Buffett comes into play. The Oracle of Omaha suggests the right course of action for most people is to simply invest their money in a low-cost index fund, particularly one that tracks the performance of the broad market S&P 500 index. One exchange-traded fund (ETF) of this type that comes to mind is the Vanguard S&P 500 ETF (NYSEMKT: VOO). Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Investors who choose this path and follow it consistently put themselves in a position to be rewarded over time. For example, investing just $1,000 per month in this ETF could result in a portfolio balance of $245,000 in 10 years. Here's what you need to know. Using history as a guide to the future In the past decade, the Vanguard S&P 500 ETF has produced a total return of 244%, with dividends reinvested. That's a fantastic outcome, likely buoyed by huge capital inflows into passive investment options over active strategies, generally solid economic growth, and the rise of several dominant tech enterprises. That trailing 10-year gain puts its compound annual growth rate at about 13% -- well ahead of the market's long-run average of 10% annually. For the sake of this article, let's assume that the next 10 years will resemble the last decade when it comes to returns. Of course, nothing is guaranteed, and the future is inherently unpredictable. But if you invest $1,000 per month between now and 2035 (for a total of 120 investments), you'd have around $245,000 in a decade. This is the power of dollar-cost averaging. You might think that to succeed as an investor, you have to make decisions like a pro and try to correctly time the market. The intention of buying low, selling high, and repeating the process sounds good in theory. However, it's virtually impossible to do well on a consistent basis. That's why a dollar-cost averaging approach makes the most sense: If you add more money to your portfolio consistently at regular intervals, you can be assured that you're taking advantage of the inevitable ups and downs of the market. Other benefits of this winning strategy Knowing that $1,000 per month can end up becoming $245,000 should be enough to get any investor excited about putting money to work in the stock market. There are other clear benefits to adopting this no-brainer strategy. For one, there's a strong chance the portfolio will beat a majority of the experts. Data shows that the performances of most actively managed funds lag the S&P 500 over long stretches of time. This doesn't prevent fund managers from charging high fees that further eat away at the returns of their investors. The Vanguard S&P 500 ETF, on the other hand, has an expense ratio of just 0.03%. That's a charge of $3 a year for every $10,000 a person has invested in the fund. That's hard to beat. Another benefit is that this is a hassle-free approach. Investors don't need fancy degrees or certifications, expert financial analysis skills, or hours of free time every week to listen to earnings calls. Putting money into the Vanguard S&P 500 ETF on a monthly basis is essentially an automatic investment allocation. It couldn't be simpler. It instantly provides investors with broad diversification into 500 of the largest U.S. companies. The ETF has exposure to all sectors, from technology and financial services businesses to energy and utilities. It's a bet on the growth of the American economy and on the premise that it will continue doing what it has always done. This seems like a smart bet to make. Buying $1,000 worth of the Vanguard S&P 500 ETF every month should put you on the path to building your wealth in the next decade and beyond. Should you invest $1,000 in Vanguard S&P 500 ETF right now? Before you buy stock in Vanguard S&P 500 ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vanguard S&P 500 ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $870,207!* Now, it's worth noting Stock Advisor 's total average return is988% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 9, 2025
Globe and Mail
3 hours ago
- Globe and Mail
Foxconn Exports 97% of India-Made iPhones to U.S. to Avert China Tariffs
Apple's (AAPL) largest supplier Foxconn has ramped up exports of India-made iPhones to the U.S. to avoid the hefty tariffs on Chinese goods. According to a Reuters report citing official customs data, an average of 97% of iPhones produced in India were shipped to the U.S. between March and May. The data shows a stark jump in exports of Indian iPhones compared to the 50% monthly average recorded in 2024. India faces a baseline 10% tariff, while Trump has proposed a revised 55% tariff on Chinese imports following the U.S.-China trade deal. Confident Investing Starts Here: China has been the primary manufacturing hub for iPhones, with roughly 80% of U.S.-bound iPhones amounting to about 60 million units annually, originating from the mainland. The sharp redirection of orders to India highlights Apple's determination in skirting the hefty tariffs imposed by the U.S. government on Chinese goods. President Donald Trump aims to bolster America's manufacturing industries by implementing these tariffs, but large corporations are clearly finding alternative solutions to circumvent them. China Strengthens Its Strategy on India-Made iPhones Apple has manufacturing bases in several countries, including the Netherlands, Britain, and the Czech Republic. However, the company has recently grown increasingly dependent on India's manufacturing expertise. Despite several warnings from Trump to stop producing iPhones in India, CEO Tim Cook seems to be happily ignoring them. The company is said to have made special arrangements at the Chennai airport in Tamil Nadu state, its key iPhone export hub, to shorten customs clearance time from 30 hours to just six hours. Between March and May 2025, Foxconn exported iPhones worth $3.2 billion from India, with a majority destined for the U.S. market. In May alone, India exported $1 billion worth of iPhones to the U.S., following a record $1.3 billion in March. Notably, in the first five months of this year, Foxconn has already shipped India-made iPhones worth $4.4 billion to the U.S., compared to exports of $3.7 billion for the whole of 2024. In March, Apple sent six special chartered flights from India to the U.S., exporting the bulk of iPhones 13, 14, 16 and 16e models worth roughly $2 billion, just before Trump's global tariffs were expected to take effect. Apple's other Indian supplier, Tata Electronics, also exported 86% of its March and April iPhone production to the U.S., a significant increase from the 52% average recorded last year. Although India is promoting itself as a smartphone manufacturing hub, it still incurs high import duties on certain components, making manufacturing more expensive in India compared to Vietnam and Mexico. Is Apple a Good Stock to Buy Now? Analysts remain divided on Apple's long-term stock trajectory due to ongoing tariff-related uncertainty. On TipRanks, AAPL stock has a Moderate Buy consensus rating based on 16 Buys, nine Holds, and four Sell ratings. Also, the average Apple price target of $226.94 implies 13.9% upside potential from current levels. Year-to-date, AAPL stock has lost 20.3%. See more AAPL analyst ratings
